ACTRN12612000269831
Not yet recruiting
未知
A 12-months parallel group randomised trial of patients with Chronic Obstructive Pulmonary Disease (COPD) comparing provision of a COPD action plan with dispensed antibiotics and oral steroids, against an action plan without dispensed medications, on action plan adherence and quality of life
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Sponsor
- Royal Prince Alfred Hospital
- Enrollment
- 90
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Physician Diagnosis of COPD
- •Post bronchodilator FEV1/FVC \<0\.7
- •Patient is enrolled in the respiratory chronic care program\- a program based at Royal Prince Alfred Hospital Sydney Australia that provides regular planned home vists for patients with COPD, within Royal Prince Alfred hospitals catchment area.The program offers continuing health support through education and assistance to patients and their carers. This program augments existing respiratory services by enhancing communication and coordination of care between hospital, community services and general practitioners.
- •This care is provided by specialist nurses and physiotherapists.
Exclusion Criteria
- •Treating clinician or respiratory chronic care team believes that the patient is unsuitable eg poor comprehension, inability to follow an action plan
- •Severe uncontroled other diseases that would likely interfere with study outcomes.
- •Active malignancy other than skin cancer.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-001172-12-ESovartis Pharma Services AG576
Active, not recruiting
Phase 1
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)Chronic obstructive pulmonary disease (COPD)MedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-001172-12-BEovartis Pharma Services AG576
Active, not recruiting
Not Applicable
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with chronic obstructive pulmonary disease (COPD)EUCTR2012-001172-12-BGovartis Pharma Services AG576
Active, not recruiting
Phase 1
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with COPDEUCTR2012-001172-12-FIovartis Pharma Services AG629
Active, not recruiting
Not Applicable
Efficacy and safety of QMF149 vs. salmeterol xinafoate/fluticasone propionate in patients with COPDCOPDMedDRA version: 14.1Level: LLTClassification code 10010952Term: COPDSystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2012-001172-12-DKovartis Pharma Services AG576